Looking Back at ASCO 2022
Dave Li, MD, PhD. KCR Principal Consultant
The ASCO Annual Meeting was held from June 3–7, 2022, in Chicago. After two years of interruption by the COVID-19 pandemic, this was the first time since 2019 that both an in-person and online platform to present the latest advancements in cancer research, treatment, and patient care was available to attendees.
This year’s theme was Advancing Equitable Cancer Care Through Innovation, with more than 5,198 abstracts and posters presented, along with 85 livestream presentation sessions. The meeting covered a broad spectrum of topics in clinical oncology related therapeutic areas, including clinical developments of new therapeutic agents, recent and late breaking treatment advances in many cancer types and stages in major some cancers such as colorectal, prostate, breast, lung, and hematologic malignancies, and others such as cancer screening and prevention, disparities in accessing care, innovative treatment modality in combinations of chemotherapy and immunotherapy, etc.
The opening session featured a Presidential Address from Everett Vokes, MD, FASCO, as well as guest speakers André Michel Ilbawi, MD, from the World Health Organization, and Douglas R. Lowy, MD, from the National Cancer Institute.
The Plenary Session offered significant results from recently completed Phase 3 clinical trials which could change the current standard of care of clinical practices for their respective cancers. The standouts included:
1. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. (Abstract LBA3, Plenary).
The clinical trial involved n = 557 patients with metastatic breast cancer who were HER2-low. Two-thirds were randomized to the experimental drug, trastuzumab deruxtecan (Enhertu); the rest assigned to standard chemotherapy. In the experimental cohort with trastuzumab deruxtecan, progression free survival (PFS) for about 10.1 months and overall survival (OS) for 23.9 months vs. PFS for 5.4 months and OS for 16.8 months for those who with standard chemotherapy. The findings show that trastuzumab deruxtecan, already approved in breast cancer and certain gastric cancers, reduced the risk of disease progression or death by 50% compared with chemotherapy for HER2-low patients with both hormone receptor (HR)–positive (HR+) and HR-negative (HR–) disease which is highly significant. The study has been published in NEJM on June 5, 2022 (https://www.nejm.org/doi/full/10.1056/NEJMoa2203690)
2. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. (Abstract LBA1, Plenary).
The findings showed that panitumumab plus FOLFOX yields better results in OS, ORR, and curative resection rate compared to bevacizumab plus FOLFOX in patients with left-sided RAS wild-type metastatic colorectal cancer. Of note, within this study patient population, the OS is the longest duration ever reported in a prospective phase 3 trial as first line treatment in mCRC setting.
ASCO is a conference dedicated to improving cancer research and cancer care, and it was evident that the industry is doing just that. KCR was honored to participate and learn from impactful clinical teams who are advancing clinical practices and improving patient outcomes every day.
KCR is a clinical development solutions provider creating value for biotechnology and pharmaceutical organizations. Founded in 1997, our expert teams support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates across North America, Europe, and Australia, with main office locations in Boston, US, Berlin, Germany, and Warsaw, Poland. Our geographical coverage across 25+ countries, cutting-edge technical capabilities and tailored offerings allow for the optimized delivery of solutions to develop life-changing therapies. KCR offers access to an estimated population of 1.1 billion people. For more information visit www.kcrcro.com.
We see the human behind every number.